The Phase IIb trial was designed to explore the safety, tolerability and efficacy of Spheramine, the company’s novel cell-based therapy for the potential treatment of moderate to advanced Parkinson’s disease.
Marc Rubin, president and CEO of Titan, said: “We are disappointed by these data as we have been diligently working to address the critical unmet medical need facing Parkinson’s patients. Although we do not expect our partner Bayer Schering Pharma to continue development of this product, we will continue to analyze and assess these data to better understand the study findings and determine our next steps.”